title: Cancer gene therapy with targeted adenoviruses.
abstract: BACKGROUND
  Clinical experience with adenovirus vectors has highlighted the need for improved delivery and targeting.
  
  
  OBJECTIVE
  This manuscript aims to provide an overview of the techniques currently under development for improving adenovirus delivery to malignant cells in vivo.
  
  
  METHODS
  Primary research articles reporting improvements in adenoviral gene delivery are described. Strategies include genetic modification of viral coat proteins, non-genetic modifications including polymer encapsulation approaches and pharmacological interventions.
  
  
  CONCLUSIONS
  Reprogramming adenovirus tropism in vitro has been convincingly demonstrated using a range of genetic and physical strategies. These studies have provided new insights into our understanding of virology and the field is progressing. However, there are still some limitations that need special consideration before adenovirus-targeted cancer gene therapy emerges as a routine treatment in the clinical setting.
authors.affiliation: University of Oxford, Department of Clinical Pharmacology, Old Road Campus Research Building, OX3 7DQ, Oxford, UK.
authors.forename: Houria
authors.initials: H
authors.lastname: Bachtarzi
authors.forename: Mark
authors.initials: M
authors.lastname: Stevenson
authors.forename: Kerry
authors.initials: K
authors.lastname: Fisher
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000595:Amino Acid Sequence; D000818:Animals; D018033:Antibodies, Bispecific / Q000737:chemistry / Q000235:genetics; D036022:Capsid Proteins / Q000737:chemistry / Q000235:genetics; D004195:Disease Models, Animal; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D050506:Mutant Chimeric Proteins / Q000235:genetics; D009369:Neoplasms / Q000628:therapy*
chemical_list: D018033:Antibodies, Bispecific; D036022:Capsid Proteins; D050506:Mutant Chimeric Proteins